TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of residents having vitamin D and calcium supplements daily
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chronic Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of participants contacted that are enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in modified International Index of Erectile Dysfunction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Patient Health Questionnaire-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Depression Anxiety Stress Scales-Chinese Version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average time for return to potency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Average time for return to continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Attendance for MOUD
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Remission rate of parasitic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spermatozoa DNA Methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: rate of development of relapsing or repeat peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Weight loss percentage from baseline at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of weight loss at week 24 after enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct costs (supplies)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct costs (working hours)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost minimization and consequential cost analysis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Flexilevel Scale of Shoulder Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration from surgery to first PCA administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percentage of serum uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI gastric emptying rate (T50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 13-Carbon labelled Sodium Acetate Breath test gastric emptying rate (T50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite biological score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in PTSD Checklist (adapted PCL-5) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological signal characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological tremor signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identify exacerbations of psychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rod fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serious adverse device effect (SADE)-free rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of all-cause hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient-reported health-related quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reproductive neuroendocrinology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Success rate of effective occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of pain associated with Trigeminal Neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goniometer (range of motion measurement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of clinically significant study drug-related adverse events requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Level of glial fibrillary acid protein (GFAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative analgesia (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients who developed hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients who developed diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdomen measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of grade 2.5 RTOG radiodermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor-to-Background Ratio (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of cutaneous disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving Seroprotection at Week 4 (Observed Case)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Seroprotection at Week 4 (Non-responder Imputation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity of lesions detected by 18Fludarabine PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Numeric Rating Scale of Chronic Phantom Limb Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic responses to a 2-hr oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma endocannabinoids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Theta-Gamma Coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parent-Reported ADHD & Working Memory-Related Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Working Memory Test Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tau PET SUVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regression of NASH fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Spanish Version of the Yesavage Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30-seconds Chair Sit to Stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment response in aTTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) scores < 22
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mini-mental state examination (MMSE) < 27
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: modified Rankin Scales (mRS) > 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity after the second dose of the BNT162b2 mRNA Covid-19 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total myocardial ischemia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular ejection fraction difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse reactions within 48 hours after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in IgG ELISA antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum bilirubin removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Physical Activity Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Physical Activity Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Physical Activity Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The primary outcome
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Change in NfL Levels Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Safety Events at 7 days Post Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Safety Events at 30 days Post Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Safety Events at 12 Months Post Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Persistent AF Acute Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Persistent AF Chronic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture healing situation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of serum Uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of excretion of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in stride length at identical walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of device related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: 75% of patients alive and progression free at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of participants reporting serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Daily dyspnea score during weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Daily presence of dyspnea during weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) from time 0 to last quantifiable time point (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment Net Gain (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of physical activity (light)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baseline Minnesota Living with Heart Failure Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the concentration curve during one dosing interval at steady state (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mullen Early Learning Scales (MSEL)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of referral
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain management assessed by NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 times sit to stand test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of repetitions of deadlift with 20 kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall haemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain with active hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative morphine equivalent dose over 48 post-operative hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Life's Essential 8 (LE8) Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Patient Health Questionnaire-9 (PHQ-9) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder-7 (GAD-7) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Quality of Life In Alzheimer's disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Perceived Change Index- Caregiver QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activity of CB-NK infusion in combination with cetuximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in quality of life in persons living with dementia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in plasma nitrite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with adverse events of special interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dietary behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Adverse Device-related Events (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Serious Adverse Device-related Events (SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Average area under the curve (AUC) of the FACIT-D diarrhea subscale score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Brief Child Abuse Potential Inventory (BCAP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Parenting Skills Assessment 10th Edition (PSA-10)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Center for Epidemiological Studies Depression Scale (CESD-10)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cervical Ripening Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior (FLACC scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleye App Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: M-chart Scores (horizontal and vertical)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motricity Index of dorsi flexors, knee extensors and hip flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return to baseline function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rescue analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Circulating levels of Angiopoietin-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interaction of VAPB with ORP1L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of unplanned hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Rate of unplanned ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Methotrexate Polyglutamate Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rate of chronic HDV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Retention rate of secukinumab therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative pulmonary complications outcome completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUClast of CKD-843 A, CKD-843 B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of CKD-843 A, CKD-843 B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-90days of CKD-843 A, CKD-843 B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of CKD-843-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of CKD-843-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Normalization of free triiodothyronine (FT3) and free thyroxine (FT4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: qEEG change: within
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: qEEG change: between
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptomatic fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient mobility level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical recovery status after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Short Chain Fatty Acid (SCFA) butyrate levels - stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Short Chain Fatty Acid (SCFA) butyrate levels - plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in propionate levels - stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in propionate levels - plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in acetate levels - stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Grade 3 or Higher Treatment-Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: performance indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of precancerous actinic keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Treatment Satisfaction Questionnaire for Medication 1.4
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nonmedical opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: Linear hamstring flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Angular hamstring flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thoracic spinal curvatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lumbar thoracic spinal curvatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pelvic Tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Shoulder Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Shoulder Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Shoulder Functional Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Shoulder Muscle Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects achieving a titer ≥1:40 at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects reporting solicited local and systemic signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CCQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes